One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
Clinical trial NCT01139021 · COMPLETED
Trial details
- NCT number
- NCT01139021
- Sponsor
- Novartis Vaccines
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2010-06-01
- Primary completion
- 2010-11-01
- Enrollment
- 508
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.